<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5B9602DA-AB9C-4AB7-89DA-949F5BDEB1FE"><gtr:id>5B9602DA-AB9C-4AB7-89DA-949F5BDEB1FE</gtr:id><gtr:name>Roche Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53F5B935-8A59-470F-B49C-AB17082C2BC0"><gtr:id>53F5B935-8A59-470F-B49C-AB17082C2BC0</gtr:id><gtr:name>Philips research cambridge</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6161E56-8D19-4789-830F-1528216FD2B6"><gtr:id>B6161E56-8D19-4789-830F-1528216FD2B6</gtr:id><gtr:name>MRC Biostatistics Unit</gtr:name><gtr:address><gtr:line1>Institute of Public Health</gtr:line1><gtr:line2>University Fovie Site</gtr:line2><gtr:line3>Robinson Way</gtr:line3><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2SR</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6161E56-8D19-4789-830F-1528216FD2B6"><gtr:id>B6161E56-8D19-4789-830F-1528216FD2B6</gtr:id><gtr:name>MRC Biostatistics Unit</gtr:name><gtr:address><gtr:line1>Institute of Public Health</gtr:line1><gtr:line2>University Fovie Site</gtr:line2><gtr:line3>Robinson Way</gtr:line3><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2SR</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5B9602DA-AB9C-4AB7-89DA-949F5BDEB1FE"><gtr:id>5B9602DA-AB9C-4AB7-89DA-949F5BDEB1FE</gtr:id><gtr:name>Roche Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53F5B935-8A59-470F-B49C-AB17082C2BC0"><gtr:id>53F5B935-8A59-470F-B49C-AB17082C2BC0</gtr:id><gtr:name>Philips research cambridge</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B0F68442-193C-4689-BD80-7E8FB13588A3"><gtr:id>B0F68442-193C-4689-BD80-7E8FB13588A3</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Mander</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1302%2F2"><gtr:id>6F9EA014-4518-40D8-9057-B5651D0CE8EC</gtr:id><gtr:title>Adaptive clinical trials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1302/2</gtr:grantReference><gtr:abstractText>Explain, in simple lay language, the outcomes and significance of the research. You should include what the research is trying to achieve and why this is important, and brief notes on the context of the research and the methods (see Guidance Notes).
Classically designing a clinical trial involves making assumptions about various attributes, such as the treatment effect, before any data are collected. The aim of our programme is to introduce novel designs that are more flexible. The rigidity of the classic design can lead to failed studies due to wrong assumptions such as using an optimistic treatment effect to limit the size of the study. Our novel designs will allow the use of accrued information in many ways; this includes stopping the study early for futility or efficacy, re-assessing the size of the study and recruiting more patients if need be altering dose choices during the study and identifying subgroups of patients who respond the best to treatment. Our overall goal is to minimise the number of people needed within a study whilst maintaining the statistical rigour needed to correctly answer the scientific questions.</gtr:abstractText><gtr:technicalSummary>Given the increase in costs and high risk of developing new interventions smarter clinical designs are needed to make the best use of limited resources. The aim is that the leaner development plans will require fewer patients and shorter timelines. Our programme builds on that of the past where we have contributed to the design of numerous trials and continue to build collaborations in the area of adaptive designs. Most of the Hub Network for Trials Methodology Research stakeholders identified the need for more methodological research in the area of adaptive designs. This program can expand its research, training and software provision to meet this need and enable the translation of theory into future clinical trial practice. We aim to develop new trial designs to handle multiple treatments and multiple interim analyses that minimise the expected number of patients. There is an increasing need to consider diseases as multiple phenotypes and to find treatments that are effective for particular subgroups. Our methods aim to minimise the time of the clinical development and the amount of exposure time for patients whilst obtaining robust evidence for treatment safety and/or efficacy.

Each adaptive design is tailor-made for each clinical situation and the methodological problems are diverse. A clear example of this is the increasing need to design phase I trials for drug combination products. Currently phase I trial designs are very conservative using inefficient rule-based designs. We aim to not only develop better methods but to apply them in real trials, promote them in the clinical community and support clinical trials statisticians. We propose to develop more generalised methodology, such as methods that are robust to model assumptions, that can be applied across a broad range of trials to improve accessibility.

Of particular interest are study designs that can stop early and thus achieving a smaller expected sample size. Sample size re-estimation is another key area, where uncertain sample size parameters can be estimated part-way through a trial; we want to find optimal ways of how to do sample size re-estimation and how to use intermediate outcomes in these calculations. 

Future clinical development will involve using more information from intermediate markers of efficacy and/or predictive/prognostic markers to help reduce the time and resources needed to get treatments to bedside. Many of our future proposals are looking to extend current methodology to optimally incorporate these new developments.</gtr:technicalSummary><gtr:fund><gtr:end>2016-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>599109</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SMARTer trial collaboration</gtr:description><gtr:id>8A90F647-A947-47A6-8AAC-B3FA4646FD13</gtr:id><gtr:impact>We have submitted a paper on the trial design and a grant application to the HTA efficient trial design call (currently at outline stage).</gtr:impact><gtr:outcomeId>545b8158e9f9c5.37127388-1</gtr:outcomeId><gtr:partnerContribution>Input on the design and clinical expertise. They have also written a grant application to fund the trials.</gtr:partnerContribution><gtr:piContribution>I have provided expertise on statistical design of adaptive clinical trials to develop a suitable clinical trial design for the needs of the collaborators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AZ - Jodrell phase I</gtr:description><gtr:id>3DAAF0FD-3D13-49D1-871A-53375A86C831</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>5457877ba18ef8.15835658-1</gtr:outcomeId><gtr:partnerContribution>Shortlisting and recruiting</gtr:partnerContribution><gtr:piContribution>We have only just initiated this collaboration so we have been shortlisting and trying to recruit</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Cancer Trials Centre (CCTC)</gtr:department><gtr:description>Cambridge CTU</gtr:description><gtr:id>CCBB955D-9FFA-4300-A425-27BA81659850</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>545788c55c7b88.77882432-1</gtr:outcomeId><gtr:partnerContribution>They collaborate with us on clinical trial designs</gtr:partnerContribution><gtr:piContribution>We collaborate on several trials and have a joint position. We also provide computing to Simon Bond</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Maxine's PhD</gtr:description><gtr:id>6615209B-FE1B-4D60-A5D4-E5DFD2BB87C8</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>54578705f3b840.66320226-1</gtr:outcomeId><gtr:partnerContribution>Partners give scientific and practical guidance into the project</gtr:partnerContribution><gtr:piContribution>I am the academic supervisor of this CASE award, the industry partners are within GSK. I give the main methodology direction of the project</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Philips Research Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Philips Research Cambridge collaboration</gtr:description><gtr:id>260974F7-AB7C-4CF8-88B7-EDD25BDC9A82</gtr:id><gtr:impact>The student (Lisa Law) started in October 2013 and has been upgraded to full Ph.D. student status in October 2014. During her time as a student, Lisa published two papers. Unfortunately Lisa chose to drop out of the PhD programme in 2016 and submitted what she had done up to that point for a MPhil degree, which she received successfully.</gtr:impact><gtr:outcomeId>545b80c1ad7fa8.17581498-1</gtr:outcomeId><gtr:partnerContribution>Individuals at Philips Research Cambridge have provided expertise on telehealth trials and have hosted the student for a research visit. They also provided a financial contribution to the EPSRC case award that funds the studentship.</gtr:partnerContribution><gtr:piContribution>I am the academic supervisor for a Ph.D. student on the subject of 'Adaptive designs for telehealth trials'</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lancaster University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MAMS grant</gtr:description><gtr:id>DA148F31-A55C-4A96-9EE3-D1A545309049</gtr:id><gtr:impact>Multiple papers published since 2012 (recorded under publications).
Successful grant application.</gtr:impact><gtr:outcomeId>545b7e470bd1a7.63532684-1</gtr:outcomeId><gtr:partnerContribution>Dr Thomas Jaki has provided complementary expertise into the writing of papers and the grant application.</gtr:partnerContribution><gtr:piContribution>Provided input to multiple submitted papers, including two in 2013/2014, that covered multi-arm multi-stage trials and phase II oncology trials. I provided input into writing a grant that was funded by the MRC methodology research panel. I was a co-investigator on this grant.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AZ - Jodrell phase I</gtr:description><gtr:id>B830DF62-4A58-484F-9CF6-A84A5FB5A453</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>5457877ba18ef8.15835658-2</gtr:outcomeId><gtr:partnerContribution>Shortlisting and recruiting</gtr:partnerContribution><gtr:piContribution>We have only just initiated this collaboration so we have been shortlisting and trying to recruit</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CRUK grant</gtr:description><gtr:id>918859B5-1A99-41C7-97A1-1039AAFFBCAE</gtr:id><gtr:impact>With individuals at the University of Birmingham, I have successfully applied for a Cancer Research UK grant, to start in Jan 2015.</gtr:impact><gtr:outcomeId>545b7f8b5254a8.30961926-1</gtr:outcomeId><gtr:partnerContribution>Individuals at the University of Birmingham provided clinical and applied statistical expertise that has helped us jointly develop a programme of work for a grant application.</gtr:partnerContribution><gtr:piContribution>I have provided expertise in efficient statistical analysis of phase II oncology trials using the RECIST criteria.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roche Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Roche phase I trial design</gtr:description><gtr:id>A491BD14-902C-4756-B77C-A84290CCE98F</gtr:id><gtr:impact>None yet, it is still early</gtr:impact><gtr:outcomeId>5457881bea9b29.09437740-1</gtr:outcomeId><gtr:partnerContribution>The partners have listened and are committed to trying methods out in practice. Currently one of the their phase I trial designs is using the dual-agent design PIPE in one of their early phase trials (ClinicalTrials.gov Identifier: NCT02760797).</gtr:partnerContribution><gtr:piContribution>We have engaged with industry to try and implement methods in practice. We have had some meetings and some presentations but also we have some joint work ongoing to help implement the PIPE design methodology</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>Diabetes Research</gtr:description><gtr:id>AB7FD49D-9C98-4AFF-B3F2-415FF57AB564</gtr:id><gtr:impact>Drafted publications and presentations</gtr:impact><gtr:outcomeId>5457815ca9e398.11808737-1</gtr:outcomeId><gtr:partnerContribution>They ran the trial and gave the scientific steer</gtr:partnerContribution><gtr:piContribution>Involved in multiple trials involving Il-2 dose/frequency finding</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute of Public Health</gtr:department><gtr:description>Polypill</gtr:description><gtr:id>46466A4D-8E13-4D4F-9C4E-D34A324F1961</gtr:id><gtr:impact>All outputs are still being developed</gtr:impact><gtr:outcomeId>545785b7ea3399.58836572-1</gtr:outcomeId><gtr:partnerContribution>Scientific direction and running trial</gtr:partnerContribution><gtr:piContribution>Co-applicant on program grant, developing trial design with research team.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Nutrition Research Unit</gtr:department><gtr:description>WRAP study</gtr:description><gtr:id>8EF63323-03DD-46D2-A9F2-1B433CBF932B</gtr:id><gtr:impact>No direct outputs yet</gtr:impact><gtr:outcomeId>54578624466399.05152587-1</gtr:outcomeId><gtr:partnerContribution>Scientific direction and running the trial</gtr:partnerContribution><gtr:piContribution>Trial design expertise and how to handle missing data</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Dose ranging talk (Cambridge) invited by the Cambridge Discussion Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D781E49C-A518-42EE-AB3E-89480D4273EB</gtr:id><gtr:impact>Talk sparked a debate about these methods.

Made some industry links within Roche and Astra Zeneca</gtr:impact><gtr:outcomeId>545b89c79bc159.85832755</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited to give a departmental seminar on adaptive designs (Norwich)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>546DCB2F-C84B-439B-B72B-FD03D146A267</gtr:id><gtr:impact>Around 30 members of the clinical trials unit attended my talk on adaptive clinical trials, there was a great deal of interest and promises of future collaboration as there was a recognition that these methods will be needed in the near future</gtr:impact><gtr:outcomeId>56dea5b34930e9.22548826</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk for the Breathlessness conference (Cambridge)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0DCDBF04-BC8B-4D9A-8673-7AB4134A29F0</gtr:id><gtr:impact>Adrian Mander gave a presentation on the various ways to adapt clinical trials to the area of palliative and end of life care. There has been numerous discussions since the talk by email with plans to produce a paper introducing this area to the wider audience undertaking these challenging trials.</gtr:impact><gtr:outcomeId>56dea62d2bc556.02107565</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI talk on phase I trials (Liverpool)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ACEE857D-F84A-4649-B291-03519F840643</gtr:id><gtr:impact>There was some debate and discussion.

None so far but this was the start of raising the awareness of better trials in oncology</gtr:impact><gtr:outcomeId>545b8c012cc240.04418762</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation at an early phase clinical conference (Paris)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>598775DD-45CD-4FE5-B197-18955A61A713</gtr:id><gtr:impact>I presented a novel clinical trial design on dual-agent dose escalation, there was a lot of interest from academics and industry. Since then I have worked closely with a member of Roche pharmaceuticals on how to implement these methods in practice.</gtr:impact><gtr:outcomeId>56dea484897b61.66015935</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Clinical Trials in Small Populations workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D6338764-8A71-4265-86DF-EE7A344C8C64</gtr:id><gtr:impact>SV was co-organiser of worksop, gave a tutorial on `Response-adaptive randomisation' during Day 1 and also contributed to one of the talks during Day 2 entitled 'Bringing patient population size into clinical trial design using response-adaptive randomisation'.</gtr:impact><gtr:outcomeId>56df144e56f477.57934081</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Adaptive Designs Talk at PSI conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C700F90-F766-41D7-927C-58BE018345E3</gtr:id><gtr:impact>This talk raised the awareness of the Hub Network activities in adaptive trial designs. There was some discussion of the methods and discussion about being available for consultative purposes.

No notable impacts</gtr:impact><gtr:outcomeId>545b8ad5a8e794.97494580</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk on early phase clinical trial designs (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>31C8B64C-24A4-4C7D-B674-E44237EC8D50</gtr:id><gtr:impact>80 members of clinical trials units attended a workshop run by the NCRI, the talk on early phase designs was aimed at changing practice and how we design phase I trials.</gtr:impact><gtr:outcomeId>56dea5176c6eb4.91538911</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at the local RSS NW group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BB3BA63C-26C8-4536-9088-A618CBA2FEA1</gtr:id><gtr:impact>A review talk on the multiple bandit-based designs publications of Sofia Villar</gtr:impact><gtr:outcomeId>58bebb8f614ea9.66458197</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Armitage Lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4A644A4D-69F3-43D8-944F-A04563883FA8</gtr:id><gtr:impact>Annual workshop and lecture created and hosted by the MRC Biostatistics Unit, to honour the immense contributions of Professor Peter Armitage who was at the unit from 1947 to 1961, and whose work is recognised throughout the world as achieving a successful balance between methodological rigour and applied commonsense, to which all statisticians aspire. An eminent medical statistician visits for a week and works with members of the unit. The highlight is the Armitage Lecture, where more than 100 delegates attend. This event raises the unit research profile and creates new collaborations.</gtr:impact><gtr:outcomeId>58b6f9f83c8094.78936665</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.mrc-bsu.cam.ac.uk/news-and-events/armitage-lectureships-and-workshops/</gtr:url><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dose finding talk (Charleston)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5AD62446-CCC2-430D-9794-FD006B9BAC62</gtr:id><gtr:impact>Talk sparked a discussion on various dose-ranging aspects

No immediate impacts</gtr:impact><gtr:outcomeId>545b894d467dd7.19044150</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Design Service (LONDON)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>03615275-9CC3-4851-9E36-50C759F85EB7</gtr:id><gtr:impact>I was invited to talk about adaptive clinical trials as part of a workshop of talks. There is a call for novel designs and my talk covered various methods that can be used to make trials more efficient</gtr:impact><gtr:outcomeId>56dea3dd867c64.14076893</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Lancaster University - Methodological work to make bandit models suitable to design (and improve) multi-armed clinical trial</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D110DFFD-4819-48F0-A8FF-B03A87AF8D52</gtr:id><gtr:impact>SV invited speaker at workshop that gathered worldwide experts on ''bandit problems&amp;quot; (reinforcement learning bandits, restless bandits, non-parametric bandits, Bayesian bandits, etc., ) to discuss recent methodological advances and applications. SV spoke about recent methodological work to make bandit models suitable to design (and improve) multi-armed clinical trials.</gtr:impact><gtr:outcomeId>56df14f8953b38.70136318</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk on adaptive designs to Astra Zeneca</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6D70DD8F-F6FC-4D50-B897-E90900828C3F</gtr:id><gtr:impact>There was much interest in the methods and raised awareness of our group to the company

Since this talk we have secured a data sharing agreement and collaboration.
There are also 3 AZ post-docs that we have been linked with</gtr:impact><gtr:outcomeId>545b8b3f7ec3e3.76073835</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Adaptive Designs symposium at the Institute of Psychiatry</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DDFF9DAC-02D4-426D-ADE5-6EAC0724A073</gtr:id><gtr:impact>There was some interesting debates about adaptive designs

Raised our visibility in Psychiatry</gtr:impact><gtr:outcomeId>545b8b941827b8.58104129</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSU Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AD7F84CE-DDC7-49F2-87FD-4E5A83A353D9</gtr:id><gtr:impact>Unit held open day as part of MRC Festival of Medical Research. 

The aim of the open day was to welcome secondary school students and members of the general public to come to the unit, find out about the research the unit does, and to take part in activities that illustrate BSU research, with the overall theme being 'Fun with statistics'. An open day of this format was a first for the unit and overall it was a very successful event. There were 40 attendees over a 4 hour event. All attendees pre-booked and were split into 4 groups for a 1 hour session comprising of an introduction, participation in hands-on activities, and a brief careers talk. The small groups and length of session allowed for quality engagement between the scientists and the audience. 

Feedback from the attendees was very positive, and the wider MRC Festival activities that took place in Cambridge demonstrated the benefits in delivering these types of events.</gtr:impact><gtr:outcomeId>58aedd9593b1c7.34338352</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.mrc-bsu.cam.ac.uk/bsu-open-day-2016-why-are-statistics-important/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Contributed talks at the 18th INFORMS Applied Probability Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4111BE62-1756-4B6E-A7EF-07C505E138F7</gtr:id><gtr:impact>SV gave contributed talks at the 18th INFORMS Applied Probability Conference and the 7th Greek Stochastics meeting. Talk entitled &amp;quot;Novel bandit-based solutions for practical stochastic scheduling problems&amp;quot;.</gtr:impact><gtr:outcomeId>56df0ddb7bf691.88412069</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.stochastics.gr/meetings/eta/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk about adaptive enrichment designs (Institute of Cancer Research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4F308534-A214-4672-97F4-27CA2400BF0B</gtr:id><gtr:impact>We had a day long discussion about various potential collaborations

There were no massive impacts, a similar study was planned in their institute but it was too late to help improve it.</gtr:impact><gtr:outcomeId>545b8a451cf122.70499561</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>025EEBEC-6948-474F-8226-BDF5B34E2679</gtr:id><gtr:impact>Each year BSU participate in Cambridge Science Festival - members of the general public explore and discuss issues of scientific interest and concern, through a series of different events. The festival also aims to raise aspirations by encouraging young people to consider a career in science, technology, engineering or mathematics.

BSU take part over two full days - 'Science Saturday' and the 'Cambridge Biomedical Campus' day. The unit presents a stand with 4 - 5 interactive activities that each communicate a basic statistical method or idea, representing one of the four research themes in the unit. Each year a new activity is developed and delivered requiring scientific input from staff and students across the unit. Over the two days, BSU engage with approximately 500 adults and children who visit the festival.</gtr:impact><gtr:outcomeId>56ddaf762b9b60.36754298</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.sciencefestival.cam.ac.uk/</gtr:url><gtr:year>2012,2013,2014,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>654000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>EPAD-</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>E5A66BC1-5F86-4CB3-9444-628C7345F230</gtr:id><gtr:outcomeId>56dd5eb01f21a3.34547942</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17059</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC DPFS Resoure Centre</gtr:department><gtr:description>MBU grant</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>9D1E9B5D-BC34-4AA5-841F-4A8DD9CD7A90</gtr:id><gtr:outcomeId>56dd60937a1423.58722672</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>INNODIA</gtr:description><gtr:end>2022-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>DCF2EC87-A9CC-43E6-9E7E-C01D7A264C27</gtr:id><gtr:outcomeId>56dd60122eee84.14187394</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10597</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR XP grant</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>0F88F118-EE69-4155-AD44-C97F7E9D6F0B</gtr:id><gtr:outcomeId>56dd5f08d9d678.93901343</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>52826</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HTA (Epilepsy Nurse)</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>0977CC07-384E-4D9A-9638-0706E661E9CA</gtr:id><gtr:outcomeId>545a2e388d5605.90238454</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>43679</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AIM-HY</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7775D6B0-0B39-44C4-AA34-C998D5202763</gtr:id><gtr:outcomeId>56dd5fca329576.80601016</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>85434</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR- Jonathan Mant</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4FB47225-41B6-474F-A963-5F908707D1FB</gtr:id><gtr:outcomeId>56dd5f6bc63d57.84312689</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>New adaptive design mentioned as 'research highlight' in Nature Reviews Clinical Oncology</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1A1D0BD5-B18D-4D57-92F9-7D95F61221D1</gtr:id><gtr:outcomeId>56df0b2d222724.90608781</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.nature.com/nrclinonc/journal/vaop/ncurrent/full/nrclinonc.2015.138.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Using Historical Data training course</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>3FD744B8-4EE3-4E4B-B78B-741068576F2B</gtr:id><gtr:impact>Adrian Mander was invited to create a course for GSK on the use of historical data to improve the design of clinical trials. This is a hugely important issue and has the ability to make efficiency gains for early phase clinical trials. GSK are already using the techniques in practice and this course was to enable a better understanding and wider usage of these techniques</gtr:impact><gtr:outcomeId>56deaa45145601.39490074</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>The Stata module calculates multivariate statistics.</gtr:description><gtr:id>A4F8508C-D4AC-42F0-A9D5-6DDA01DFCC71</gtr:id><gtr:impact>The stata module can be used in an group sequential /MAMS clinical trial and the companion stata journal article is in preparation.</gtr:impact><gtr:outcomeId>56dea1e93d6789.30562568</gtr:outcomeId><gtr:title>MVTNorm</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>A stata module to design a continual reassessment trial</gtr:description><gtr:id>76327E20-388B-4687-A23C-557EBD9E9FD5</gtr:id><gtr:impact>There have been some downloads of this module but no references to it as of yet.</gtr:impact><gtr:outcomeId>545cc89dd8d0f8.94611037</gtr:outcomeId><gtr:title>CRM</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>A stata module to due simple imputaton</gtr:description><gtr:id>7510AFA6-4DDE-430E-B7F1-CD38B4913318</gtr:id><gtr:impact>It has been downloaded but no citations as of yet.</gtr:impact><gtr:outcomeId>545cb348a129c1.10872356</gtr:outcomeId><gtr:title>Simpute</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>Stata module to design a simon two-stage design</gtr:description><gtr:id>BFD27C50-B86A-4F50-B824-3EC1284E666C</gtr:id><gtr:impact>None so far but this was linked to a publication and those methods have been cited so this software is being used.</gtr:impact><gtr:outcomeId>545cc8e967b5b0.08166883</gtr:outcomeId><gtr:title>Simon2stage</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>17F36BCF-4A44-47D9-8662-1F8668CEF304</gtr:id><gtr:title>A crossover randomised controlled trial of oral mandibular advancement devices for obstructive sleep apnoea-hypopnoea (TOMADO).</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53755bb5952988ffaab40fd58a0f7f1b"><gtr:id>53755bb5952988ffaab40fd58a0f7f1b</gtr:id><gtr:otherNames>Quinnell TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>544a4c5b84f4f2.64163915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BA79D67-DB40-41F4-B7BD-292E6BC02F08</gtr:id><gtr:title>Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule.</gtr:title><gtr:parentPublicationTitle>Biometrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-341X</gtr:issn><gtr:outcomeId>56d6e83471e231.20115069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64AE8A4B-FFC7-4E71-8994-D0F774A0AF82</gtr:id><gtr:title>Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef3dd8d7b6622717fa234ee9778dc93f"><gtr:id>ef3dd8d7b6622717fa234ee9778dc93f</gtr:id><gtr:otherNames>Wheeler GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>58aafb7a5f8bb1.36625320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EB1EC77-B987-4726-8B27-6E05729C94EF</gtr:id><gtr:title>A Bayesian adaptive design for biomarker trials with linked treatments.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56d6e834a82855.25549387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDAE7EEB-B0A2-4116-A0BE-160A627EDBFD</gtr:id><gtr:title>Confidence intervals for the between-study variance in random-effects meta-analysis using generalised heterogeneity statistics: should we use unequal tails?</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cab0d53161368150e28f9caa0627018"><gtr:id>9cab0d53161368150e28f9caa0627018</gtr:id><gtr:otherNames>Jackson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>58aafb7c4c01b9.54627671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80929676-BBD1-43A4-96B1-30FE704EF70E</gtr:id><gtr:title>Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges.</gtr:title><gtr:parentPublicationTitle>Statistical science : a review journal of the Institute of Mathematical Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0883-4237</gtr:issn><gtr:outcomeId>56d6e8336d1b85.33431451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BCE32FB-69BB-4E2A-B903-240AF754DE5A</gtr:id><gtr:title>The Cambridge post-mastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a59e1f40bd4e6892376678e5aaea96"><gtr:id>c7a59e1f40bd4e6892376678e5aaea96</gtr:id><gtr:otherNames>Mukesh MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>544a4c5b2d76a5.83609321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43E18334-883A-4F12-B359-760710387C33</gtr:id><gtr:title>The power of phase II end-points for different possible mechanisms of action of an experimental treatment.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>56d818c3491fc6.89766679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CC41F45-EF5F-43F5-A7C3-E13562772566</gtr:id><gtr:title>Empirical Bayes estimation of the selected treatment mean for two-stage drop-the-loser trials: a meta-analytic approach.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>544a48aa58f5c4.71563365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F84D4903-9B17-45AF-A1CC-151F66C6DF03</gtr:id><gtr:title>Age and sex differences in the incorporation of EPA and DHA into plasma fractions, cells and adipose tissue in humans.</gtr:title><gtr:parentPublicationTitle>The British journal of nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2038b790bd5a10bc533b5091f65a9b0"><gtr:id>e2038b790bd5a10bc533b5091f65a9b0</gtr:id><gtr:otherNames>Walker CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1145</gtr:issn><gtr:outcomeId>544a4c5c5da6f4.22920537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2283FEA-B794-483E-9974-CA55C4E414BE</gtr:id><gtr:title>A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>544a4c5e238320.90373344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E4BD88C-8AE2-4BCA-B697-B0BB1BB5B26F</gtr:id><gtr:title>Genetic predisposition to an adverse lipid profile limits the improvement in total cholesterol in response to weight loss.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2038b790bd5a10bc533b5091f65a9b0"><gtr:id>e2038b790bd5a10bc533b5091f65a9b0</gtr:id><gtr:otherNames>Walker CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>544a4c5c8735d5.39988895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>584A550B-0248-4882-8272-190ACC879A0D</gtr:id><gtr:title>The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f1b61b7397511efbfc833269662f03a"><gtr:id>8f1b61b7397511efbfc833269662f03a</gtr:id><gtr:otherNames>Dalton LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>544a4a08e57a11.57250721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47C6A8AA-77AE-429F-82B0-874AB97C14AB</gtr:id><gtr:title>Developments in Statistical Evaluation of Clinical Trials</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-3-642-55344-8</gtr:isbn><gtr:outcomeId>545cb8546f43a9.38615333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A3EBABF-AF35-41AD-A3CF-A4BD88407BBB</gtr:id><gtr:title>Accounting for selection and correlation in the analysis of two-stage genome-wide association studies.</gtr:title><gtr:parentPublicationTitle>Biostatistics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6ede0aadb5e4a65b68f613471edca96"><gtr:id>e6ede0aadb5e4a65b68f613471edca96</gtr:id><gtr:otherNames>Robertson DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-4644</gtr:issn><gtr:outcomeId>58b6990aa82559.39267068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>827E2023-17DE-479E-A5D4-E2524634559D</gtr:id><gtr:title>Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2cb1ebd10191ec62e0de95636367469"><gtr:id>f2cb1ebd10191ec62e0de95636367469</gtr:id><gtr:otherNames>Rintoul RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>544a4c5bbd8051.23385046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>854B298C-9181-4A4E-91BA-8881065ABB14</gtr:id><gtr:title>Clinical outcomes of single versus staged hybrid repair for thoracoabdominal aortic aneurysm.</gtr:title><gtr:parentPublicationTitle>Journal of vascular surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fab711e10a7d007b674511aeb84616fd"><gtr:id>fab711e10a7d007b674511aeb84616fd</gtr:id><gtr:otherNames>Canaud L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0741-5214</gtr:issn><gtr:outcomeId>544a48ab36be57.31392579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1A26759-DAFE-4A38-81EF-CEF04B21C13D</gtr:id><gtr:title>Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge Breast IMRT trial.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a59e1f40bd4e6892376678e5aaea96"><gtr:id>c7a59e1f40bd4e6892376678e5aaea96</gtr:id><gtr:otherNames>Mukesh MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>544a4c5b5a0a98.57883438</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F59AAFA-A281-4822-A603-00779437B5D4</gtr:id><gtr:title>Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>544a4c5ac17268.81195739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F90665EE-E5AE-4DEB-9843-212934372B2D</gtr:id><gtr:title>Diagnostic accuracy of preoperative computed tomography used alone to detect lymph-node involvement at radical nephrectomy.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b37fef3683b72def1781bf8407c7856"><gtr:id>7b37fef3683b72def1781bf8407c7856</gtr:id><gtr:otherNames>Connolly SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2168-1805</gtr:issn><gtr:outcomeId>56d6e832727476.67900269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>538C2E6E-60B0-4F23-A862-9E62D1BF8E1E</gtr:id><gtr:title>Confounding underlies the apparent month of birth effect in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b75e2de0e00a7cff07ddf0dc8564c9dc"><gtr:id>b75e2de0e00a7cff07ddf0dc8564c9dc</gtr:id><gtr:otherNames>Fiddes B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>544a4a09222060.57333680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C304B01A-1BC1-4C77-A51D-57FBD23FE163</gtr:id><gtr:title>Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b01452026bc325323bfb9a5fb2196832"><gtr:id>b01452026bc325323bfb9a5fb2196832</gtr:id><gtr:otherNames>Ahern A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a8d4add9fbd00.88305063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B92484F-0FA0-487E-A54A-7A7B85FD5140</gtr:id><gtr:title>Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef3dd8d7b6622717fa234ee9778dc93f"><gtr:id>ef3dd8d7b6622717fa234ee9778dc93f</gtr:id><gtr:otherNames>Wheeler GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5a31d8753ff552.44337758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E749AC51-6408-429E-BD00-BE8C23182D8E</gtr:id><gtr:title>Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies.</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/360a808324aad78098cb2db35a75a186"><gtr:id>360a808324aad78098cb2db35a75a186</gtr:id><gtr:otherNames>Haycock PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn><gtr:outcomeId>58aafb7d60fea3.26472484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7018764E-0FA4-4DD0-9D2A-12ED8FCB50F6</gtr:id><gtr:title>Evaluation of multisystemic therapy pilot services in the Systemic Therapy for At Risk Teens (START) trial: study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c37f0470435950f0fee95c893bbfa15a"><gtr:id>c37f0470435950f0fee95c893bbfa15a</gtr:id><gtr:otherNames>Fonagy P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>544a4a098f1821.11630565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FED3E594-F689-453E-A92E-1D6239B65523</gtr:id><gtr:title>Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56a498fb492d65a7f05f7ef7fe081174"><gtr:id>56a498fb492d65a7f05f7ef7fe081174</gtr:id><gtr:otherNames>Thiesen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>544a4c5bf0c570.49264487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E1C580F-BBA3-409F-94CD-3A9FD5AB804E</gtr:id><gtr:title>Unbiased estimation for response adaptive clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>56d6e8324a5779.15385314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F35F16E-1B6A-4631-95CD-883C796139E8</gtr:id><gtr:title>HLA associations in South Asian multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/336e1a709128f07102217664888bfc24"><gtr:id>336e1a709128f07102217664888bfc24</gtr:id><gtr:otherNames>Pandit L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>56d818c3148ba2.16892088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80548558-4D5E-41E3-9304-96B37AFD6C11</gtr:id><gtr:title>Confounding in association studies: month of birth and multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b75e2de0e00a7cff07ddf0dc8564c9dc"><gtr:id>b75e2de0e00a7cff07ddf0dc8564c9dc</gtr:id><gtr:otherNames>Fiddes B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>544a4a095892c9.53095882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>146D98DB-0F77-482F-AD1C-37800B04CD75</gtr:id><gtr:title>Accelerated longitudinal designs: An overview of modelling, power, costs and handling missing data.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ae11a75b026b6f35ad1d7edc2fb8b7d"><gtr:id>1ae11a75b026b6f35ad1d7edc2fb8b7d</gtr:id><gtr:otherNames>Galbraith S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>544a4a09c0a191.05927875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F331178-3750-47E5-9513-720E5A2B8F09</gtr:id><gtr:title>Weight loss referrals for adults in primary care (WRAP): protocol for a multi-centre randomised controlled trial comparing the clinical and cost-effectiveness of primary care referral to a commercial weight loss provider for 12&amp;nbsp;weeks, referral for 52&amp;nbsp;weeks, and a brief self-help intervention [ISRCTN82857232].</gtr:title><gtr:parentPublicationTitle>BMC public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b275003b54dcc014d6b052fd913e5330"><gtr:id>b275003b54dcc014d6b052fd913e5330</gtr:id><gtr:otherNames>Ahern AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2458</gtr:issn><gtr:outcomeId>544a47bd140b79.87283502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CFF265E-0304-4C81-A800-82EDD6ABF853</gtr:id><gtr:title>INDEXABILITY AND OPTIMAL INDEX POLICIES FOR A CLASS OF REINITIALISING RESTLESS BANDITS.</gtr:title><gtr:parentPublicationTitle>Probability in the engineering and informational sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b06c40cded9b34659ad19265e1011f7"><gtr:id>1b06c40cded9b34659ad19265e1011f7</gtr:id><gtr:otherNames>Villar SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9648</gtr:issn><gtr:outcomeId>5a324d02b11a53.25401821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAC382F1-65B5-4585-8C33-E513B031CC03</gtr:id><gtr:title>Do single-arm trials have a role in drug development plans incorporating randomised trials?</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb33c74748bce8e9ac10c620100d80d1"><gtr:id>eb33c74748bce8e9ac10c620100d80d1</gtr:id><gtr:otherNames>Grayling MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>58aafb7a17d7b1.27887960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4382858B-A10E-4F34-B9AD-8E6A509C19F4</gtr:id><gtr:title>Incoherent dose-escalation in phase I trials using the escalation with overdose control approach</gtr:title><gtr:parentPublicationTitle>Statistical Papers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc206557a2a44728277b8384b0380bd6"><gtr:id>dc206557a2a44728277b8384b0380bd6</gtr:id><gtr:otherNames>Wheeler G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>587cdb3935a0a5.91419695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC0B8801-E98E-4DA6-8952-BBE1075DB5C4</gtr:id><gtr:title>A sensitivity analysis framework for the treatment effect measure used in the meta-analysis of comparative binary data from randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cab0d53161368150e28f9caa0627018"><gtr:id>9cab0d53161368150e28f9caa0627018</gtr:id><gtr:otherNames>Jackson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>544a4a0a651981.78599816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CA379B4-2848-49E0-8146-2B8CE17835AD</gtr:id><gtr:title>Some recommendations for multi-arm multi-stage trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>544a4c5cb63b37.87332430</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAC4AC58-1920-40AF-A85C-193CCA03EA7D</gtr:id><gtr:title>Group sequential designs for stepped-wedge cluster randomised trials.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb33c74748bce8e9ac10c620100d80d1"><gtr:id>eb33c74748bce8e9ac10c620100d80d1</gtr:id><gtr:otherNames>Grayling MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>5a8d4addd48305.02811019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2A43F41-451C-4FA8-A0DA-6FDE39180B6C</gtr:id><gtr:title>The challenge of a 2-year follow-up after intervention for weight loss in primary care.</gtr:title><gtr:parentPublicationTitle>International journal of obesity (2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd3e06806eb51bf6aa5f914e76bc35d6"><gtr:id>dd3e06806eb51bf6aa5f914e76bc35d6</gtr:id><gtr:otherNames>Holzapfel C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0307-0565</gtr:issn><gtr:outcomeId>544a4a0a305c18.73955567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44554C80-73AA-4749-9E11-0D330C633294</gtr:id><gtr:title>Adaptive designs for dual-agent phase I dose-escalation studies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f934bfb665c483ff80c32902af6a6d3f"><gtr:id>f934bfb665c483ff80c32902af6a6d3f</gtr:id><gtr:otherNames>Harrington JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>544a4a0a013635.63915632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C22901AE-2FBB-4C3C-A27A-74A872606D7F</gtr:id><gtr:title>Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>544a4c5ce1d005.54552144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8E709A3-D17E-47B5-8115-8968F6F2CFC4</gtr:id><gtr:title>An optimal stratified Simon two-stage design.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c73ca5960e9918f43a11542761f8fd5"><gtr:id>4c73ca5960e9918f43a11542761f8fd5</gtr:id><gtr:otherNames>Parashar D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>58aafb7a3e39b7.57605724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9465A537-74F3-4683-B749-CB73339D8FEB</gtr:id><gtr:title>Body mass index and psychiatric disorders: a Mendelian randomization study.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63ddda82c200eef42220f9787d5403fc"><gtr:id>63ddda82c200eef42220f9787d5403fc</gtr:id><gtr:otherNames>Hartwig FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58aafb7b0001a6.94886770</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D8E218F-6BD2-4DE0-96D0-270AB053A07F</gtr:id><gtr:title>Using continuous data on tumour measurements to improve inference in phase II cancer studies.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>544a4c5db43854.27580277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA5DF1C8-0839-45BB-97F6-24EEDEA3BDE9</gtr:id><gtr:title>Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/046740bad40d4cdac74a9378aaf5d6e9"><gtr:id>046740bad40d4cdac74a9378aaf5d6e9</gtr:id><gtr:otherNames>Nikolic MZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>56d818c2d0e224.66857962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66C832E4-3E66-4F0A-99ED-33B3D9ED0A4B</gtr:id><gtr:title>A Bayesian adaptive design for clinical trials in rare diseases.</gtr:title><gtr:parentPublicationTitle>Computational statistics &amp; data analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/254b5b3b1bdda3ed8097593ccd4f9e51"><gtr:id>254b5b3b1bdda3ed8097593ccd4f9e51</gtr:id><gtr:otherNames>Williamson SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0167-9473</gtr:issn><gtr:outcomeId>5a31e955759299.45197127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F08F1C64-663F-4FB3-9E44-C382E3AAA19E</gtr:id><gtr:title>Comment on: Month of birth and risk of multiple sclerosis: confounding and adjustments.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b75e2de0e00a7cff07ddf0dc8564c9dc"><gtr:id>b75e2de0e00a7cff07ddf0dc8564c9dc</gtr:id><gtr:otherNames>Fiddes B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn><gtr:outcomeId>545cb853b22a91.29433049</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3339E6A-0BC6-4725-A82F-9854A4D1DB4A</gtr:id><gtr:title>Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d23ceb7e3c56afc2a019d40d709e8c11"><gtr:id>d23ceb7e3c56afc2a019d40d709e8c11</gtr:id><gtr:otherNames>Choodari-Oskooei B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>544a48ab9debd6.52239431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6FA4E87-41A7-460D-955B-2F1D72916385</gtr:id><gtr:title>Twist-drill craniostomy with hollow screws for evacuation of chronic subdural hematoma.</gtr:title><gtr:parentPublicationTitle>Journal of neurosurgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9796ea95ff572e7e096c18c5e03fbcf4"><gtr:id>9796ea95ff572e7e096c18c5e03fbcf4</gtr:id><gtr:otherNames>Chari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3085</gtr:issn><gtr:outcomeId>544a48ab661f81.91402385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A882E628-FC5B-4F15-B762-D32CAB9BF8ED</gtr:id><gtr:title>Application of Bayesian analysis to the doubly labelled water method for total energy expenditure in humans.</gtr:title><gtr:parentPublicationTitle>Rapid communications in mass spectrometry : RCM</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3019848805ad0f2056f8b63c438c1b15"><gtr:id>3019848805ad0f2056f8b63c438c1b15</gtr:id><gtr:otherNames>Ruan Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0951-4198</gtr:issn><gtr:outcomeId>5a8d4ade1942f5.08441339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66F6BAF8-5FDE-423A-95E0-FA79C2DD2CF6</gtr:id><gtr:title>A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>544a48aacbc8c9.92212365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DA34DF8-7867-4FEA-B499-DFEB59BBB566</gtr:id><gtr:title>Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/673294f4973975b6cd4e42fcd9584292"><gtr:id>673294f4973975b6cd4e42fcd9584292</gtr:id><gtr:otherNames>Gerety EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>56d818c27b70c7.30566171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB7DC0DA-1A86-40A2-BF50-847BEB5044D4</gtr:id><gtr:title>A product of independent beta probabilities dose escalation design for dual-agent phase I trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fecdd706ba0621caf2c9730b2ad217d"><gtr:id>4fecdd706ba0621caf2c9730b2ad217d</gtr:id><gtr:otherNames>Mander AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>56d6e8329c58f0.28801100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8638753B-DA4C-433C-B1B7-1492E0EED151</gtr:id><gtr:title>Weighing Evidence &amp;quot;Steampunk&amp;quot; Style via the Meta-Analyser.</gtr:title><gtr:parentPublicationTitle>The American statistician</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-1305</gtr:issn><gtr:outcomeId>58aafb7b25ae34.76934947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9BAECD0-D6E7-4047-9A78-090B020E21C6</gtr:id><gtr:title>Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977472350f95002d92596137c29ad444"><gtr:id>977472350f95002d92596137c29ad444</gtr:id><gtr:otherNames>Ring H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58aafb7c801d56.77456610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15A1DC1D-6ECF-4535-BBC3-2D6D6A9EAF66</gtr:id><gtr:title>Capecitabine and streptozocin &amp;plusmn; cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39fb6c2d561c985a2e120be7c20f49b1"><gtr:id>39fb6c2d561c985a2e120be7c20f49b1</gtr:id><gtr:otherNames>Meyer T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>544a4c5af1a8e9.67886403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFA3E13E-E217-4974-804C-A40460D1B9FC</gtr:id><gtr:title>Design of telehealth trials--introducing adaptive approaches.</gtr:title><gtr:parentPublicationTitle>International journal of medical informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e9485f28233c88b1acfd370269bc4c"><gtr:id>30e9485f28233c88b1acfd370269bc4c</gtr:id><gtr:otherNames>Law LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1386-5056</gtr:issn><gtr:outcomeId>544a4c5a95c965.34660198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>352F0DE0-7BE0-48F4-A468-D856A4973A15</gtr:id><gtr:title>Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.</gtr:title><gtr:parentPublicationTitle>Biometrical journal. Biometrische Zeitschrift</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0323-3847</gtr:issn><gtr:outcomeId>544a48aa9db3f6.08600317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECA124B0-22E9-4219-9CE7-A27FAC151B8C</gtr:id><gtr:title>BMI as a Modifiable Risk Factor for Type 2 Diabetes: Refining and Understanding Causal Estimates Using Mendelian Randomization.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86b06e84c16348e51e6de58d42fbcc00"><gtr:id>86b06e84c16348e51e6de58d42fbcc00</gtr:id><gtr:otherNames>Corbin LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>58aafb7d36c829.98428347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88C13F2A-6D2A-4843-9854-C2242A439E7F</gtr:id><gtr:title>How to use published complete case results from weight loss studies in a missing data sensitivity analysis.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/482aef76e12176fe6fb7c1eeb9c65032"><gtr:id>482aef76e12176fe6fb7c1eeb9c65032</gtr:id><gtr:otherNames>Cresswell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>544a48abd2fc24.82968386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B28E3C01-83B1-484A-8BA2-2901AB7A85BD</gtr:id><gtr:title>Palliative treatment for symptomatic malignant pericardial effusion?.</gtr:title><gtr:parentPublicationTitle>Interactive cardiovascular and thoracic surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4896432eb737cacdb634de247fdc3922"><gtr:id>4896432eb737cacdb634de247fdc3922</gtr:id><gtr:otherNames>Jama GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1569-9285</gtr:issn><gtr:outcomeId>544a4c5a29eb52.38996272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2598F06C-991D-4699-A8E3-C21F876F5F66</gtr:id><gtr:title>Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986bc073a1ac1d3285efb05fc6f3c2d"><gtr:id>3986bc073a1ac1d3285efb05fc6f3c2d</gtr:id><gtr:otherNames>Tolkien Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d6e8334869b5.51681799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>687FD063-9BE8-4A3C-B428-8400947A1148</gtr:id><gtr:title>Meta-analysis of randomised controlled trials of oral mandibular advancement devices and continuous positive airway pressure for&amp;nbsp;obstructive sleep apnoea-hypopnoea.</gtr:title><gtr:parentPublicationTitle>Sleep medicine reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5efc03bdf5e74135fb5717842954ebaa"><gtr:id>5efc03bdf5e74135fb5717842954ebaa</gtr:id><gtr:otherNames>Sharples LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1087-0792</gtr:issn><gtr:outcomeId>56d6e8331d48d0.20389638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71D8D494-F690-4087-BF60-79FBCA11D1A9</gtr:id><gtr:title>The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>544a4c5d880096.51191510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C7E20BE-8CA1-42F7-9DC4-E5C4FF89DADC</gtr:id><gtr:title>AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef3dd8d7b6622717fa234ee9778dc93f"><gtr:id>ef3dd8d7b6622717fa234ee9778dc93f</gtr:id><gtr:otherNames>Wheeler GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>587cdb39034988.00981294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE2778E3-1271-4A0C-B7DE-7F0C30316A13</gtr:id><gtr:title>Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/469c2c686fe2b1eb96f24ab37c5ff83c"><gtr:id>469c2c686fe2b1eb96f24ab37c5ff83c</gtr:id><gtr:otherNames>Anagnostou K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>544a48aa2ab9b9.33604746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEB89D76-9239-49EA-9254-A6816A6B60E9</gtr:id><gtr:title>A multi-stage drop-the-losers design for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>544a4c5d272cf0.87597520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41D1C68E-9736-44C4-AA05-DEA254E3C00F</gtr:id><gtr:title>Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>58aafb7b71ace6.86333111</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F2587BC-59BD-405F-B489-01055C1E1322</gtr:id><gtr:title>A systematic review and meta-analysis indicates underreporting of renal dysfunction following endovascular aneurysm repair.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb602a14f97b99527d98adbf6972a8c"><gtr:id>2cb602a14f97b99527d98adbf6972a8c</gtr:id><gtr:otherNames>Karthikesalingam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>544a4c5a63a7e1.08176053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>987BF294-58EE-4023-8A54-9D5D7799FAA0</gtr:id><gtr:title>Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6ede0aadb5e4a65b68f613471edca96"><gtr:id>e6ede0aadb5e4a65b68f613471edca96</gtr:id><gtr:otherNames>Robertson DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>58b6990a290e75.66731745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BCFC25A-D363-4E4D-9C7C-A4740EE0E07D</gtr:id><gtr:title>Correcting for bias in the selection and validation of informative diagnostic tests.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6ede0aadb5e4a65b68f613471edca96"><gtr:id>e6ede0aadb5e4a65b68f613471edca96</gtr:id><gtr:otherNames>Robertson DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>56d6e832c76a53.35245233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6C10089-60A6-4245-B6F1-F67AE779AA08</gtr:id><gtr:title>An adaptive design for updating the threshold value of a continuous biomarker.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fdd8aa3b4f9e8e52982ed321d045a80"><gtr:id>9fdd8aa3b4f9e8e52982ed321d045a80</gtr:id><gtr:otherNames>Spencer AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>58aafb7a87d2d5.38219066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC81BBDB-7059-44A3-991E-9E9406292EAA</gtr:id><gtr:title>Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89a7016af5cc6a68f27c36009ebd7d46"><gtr:id>89a7016af5cc6a68f27c36009ebd7d46</gtr:id><gtr:otherNames>Waldron-Lynch F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>544a4c5c2ac2f9.84989506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E23BDDDC-4121-4BC3-90C1-5898B2A897C3</gtr:id><gtr:title>Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0daab201dc253a647828e71e001a584b"><gtr:id>0daab201dc253a647828e71e001a584b</gtr:id><gtr:otherNames>Todd JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58aafb7cce1196.74086444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50172F5D-F2B4-4924-A950-39E35A45851B</gtr:id><gtr:title>Surgeon-specific mortality data disguise wider failings in delivery of safe surgical services.</gtr:title><gtr:parentPublicationTitle>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a2b938f4d5127e1d3d660330cf874d0"><gtr:id>4a2b938f4d5127e1d3d660330cf874d0</gtr:id><gtr:otherNames>Westaby S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1010-7940</gtr:issn><gtr:outcomeId>56d6e834cbed56.39299193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>886711D8-4E8C-4BE1-83D3-095D3DB5D198</gtr:id><gtr:title>Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans.</gtr:title><gtr:parentPublicationTitle>The Journal of nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/522035b6b67bf981cdaafb5a42c061af"><gtr:id>522035b6b67bf981cdaafb5a42c061af</gtr:id><gtr:otherNames>Browning LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3166</gtr:issn><gtr:outcomeId>544a48ab06e806.95763629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C015B187-43FC-4E55-8A27-4883B67FD2EA</gtr:id><gtr:title>Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>544a4c5de3b0a8.48610451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F056A90B-07DC-4CF4-8246-3DE05B1D8F8A</gtr:id><gtr:title>Systematic review and meta-analysis of the association between frailty and outcome in surgical patients.</gtr:title><gtr:parentPublicationTitle>Annals of the Royal College of Surgeons of England</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7663d03f7360bbbe500a0b61484003d2"><gtr:id>7663d03f7360bbbe500a0b61484003d2</gtr:id><gtr:otherNames>Oakland K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0035-8843</gtr:issn><gtr:outcomeId>56d6e83672a4d9.22732668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30DDC0B2-1498-42DC-9706-7D513EF21A8A</gtr:id><gtr:title>Two-stage phase II oncology designs using short-term endpoints for early stopping.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/246931942fbf1c1ce7efc72225069e11"><gtr:id>246931942fbf1c1ce7efc72225069e11</gtr:id><gtr:otherNames>Kunz CU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>56d818c2a9be55.88593776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D125572C-1EB4-48FE-B7E1-CCA2E62F9BF3</gtr:id><gtr:title>Planning multi-arm screening studies within the context of a drug development program.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>544a4c5d5226c0.10382460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FBE4D34-E83C-4994-89A7-41AB91C7DA51</gtr:id><gtr:title>Methods to estimate the between-study variance and its uncertainty in meta-analysis.</gtr:title><gtr:parentPublicationTitle>Research synthesis methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/167b7eaef6c3589ed72839fd17f709a6"><gtr:id>167b7eaef6c3589ed72839fd17f709a6</gtr:id><gtr:otherNames>Veroniki AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-2879</gtr:issn><gtr:outcomeId>58aafb79e19123.19967255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>852561BC-B821-480F-8C8B-A1E4CC9726E4</gtr:id><gtr:title>Assessment of cognitive safety in clinical drug development.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0980c02bfccd40546661ada4b20eaaa1"><gtr:id>0980c02bfccd40546661ada4b20eaaa1</gtr:id><gtr:otherNames>Roiser JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>56d6e832ed4768.16011744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8907AB7B-52FC-454E-BB8A-60FB504B1A6F</gtr:id><gtr:title>Gaining power and precision by using model-based weights in the analysis of late stage cancer trials with substantial treatment switching.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>56d6e832224f35.07952420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>098171AD-810A-4B9A-BA32-A1A777AFFE6A</gtr:id><gtr:title>Stepped wedge cluster randomized controlled trial designs: a review of reporting quality and design features.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb33c74748bce8e9ac10c620100d80d1"><gtr:id>eb33c74748bce8e9ac10c620100d80d1</gtr:id><gtr:otherNames>Grayling MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58aafb7ca9b6c2.15169886</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1302/2</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>